Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127079 | 0.92 | CCR1 (0.58) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL2241672 | 0.92 | CCR1 (0.58) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL15470590 | 0.86 | CCR1 (0.65) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL14733132 | 0.85 | CCR1 (0.43) | CCR1CCR8TGFBR1GRM5METAP2 | |
| SCHEMBL2014872 | 0.84 | KMT2A (0.44) | TGFBR1GRM5IDH1KMT2A | |
| SCHEMBL9370182 | 0.83 | MEN1 (0.52) | KDM4EKMT2A | |
| SCHEMBL8951931 | 0.83 | CCR1 (0.47) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL9370139 | 0.80 | KMO (0.47) | GRM5METAP2KDM4E | |
| SCHEMBL12497117 | 0.79 | CCR1 (0.56) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL10370101 | 0.79 | NOS1 (0.39) | TGFBR1KDM4ENOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2012117021-A2 | NOVEL MICROBIOCIDAL OXIME ETHERS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CCR1 4630/4885CCR8 4740/4885TGFBR1 2969/4885 |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCNJ2, KCNN2, KCNN1 | CCR1 4720/4885CCR8 4640/4885TGFBR1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.